Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354166 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2848087 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL3097843 | 0.85 | SMN1; SMN2 (0.97) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL895480 | 0.84 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL31170269 | 0.84 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2712105 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL188053 | 0.83 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1939902 | 0.83 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5629949 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933306-B2 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LTD. (GB) | 2005-08-23 | — | — | US | disclosed |
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | BATTY DUNCAN (GB) | 2004-09-09 | — | — | US | disclosed |
| US-6734189-B2 | TETRAHYDRO-N-CARBOXYALKYLSULFONYLCARBOLINE DERIVATIVES, USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY INHIBITORS OF MATRIX METALLOPROTEINASE, ADAM, ADAM-TS ENZYMES, AND/OR TNF ALPHA -MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2004-05-11 | — | — | US | disclosed |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-05-15 | — | — | US | disclosed |
| EP-1286994-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-20030032652-A1 | Hydroxamic and carboxylic acid derivatives | BATTY DUNCAN (GB) | 2003-02-13 | — | — | US | disclosed |
| US-6506773-B2 | For therapy of cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration | DARWIN DISCOVERY LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| US-6469020-B2 | AS INHIBITORS OF MATRIX METALLOPROTEINASE, FOR THERAPY OF DISEASES SUCH AS DEGENERATIVE DISEASES AND CERTAIN CANCERS | DARWIN DISCOVERY, LTD. (GB) | 2002-10-22 | — | — | US | disclosed |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-02-21 | — | — | US | disclosed |
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-01-31 | — | — | US | disclosed |
| WO-2001087883-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013333-A1 | Hydroxamic and carboxylic acid derivatives | HCAR2, HCAR1, CBR1 | SMN1; SMN2 2837/4885NPC1 2475/4885RAB9A 1146/4885 |
| US-20040176362-A1 | Hydroxamic and carboxylic acid derivatives | ADAM17, ADAM10, ADAM9 | SMN1; SMN2 2499/4885NPC1 2449/4885RAB9A 3034/4885 |
| US-20030032652-A1 | Hydroxamic and carboxylic acid derivatives | ADAM17, ADAM10, ADAM9 | SMN1; SMN2 2499/4885NPC1 2449/4885RAB9A 3034/4885 |
| US-20030092727-A1 | Hydroxamic and carboxylic acid derivatives | UACA, HCAR2, HCAR1 | SMN1; SMN2 4073/4885NPC1 3532/4885RAB9A 2699/4885 |
| US-20020022635-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, HCAR3 | SMN1; SMN2 4289/4885NPC1 2740/4885RAB9A 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.